Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$3.83 USD
-0.18 (-4.49%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $3.82 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Price, Consensus and EPS Surprise
GLUE 3.83 -0.18(-4.49%)
Will GLUE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GLUE
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Other News for GLUE
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics presents preclinical data on MRT-6160
Monte Rosa Therapeutics Appoints Jennifer Champoux as COO
Monte Rosa Therapeutics promotes Champoux to COO
Monte Rosa Therapeutics Announces Leadership Team Promotions